© The Financial Times Ltd 2015 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Jul 24, 2015, the consensus forecast amongst 20 polled investment analysts covering Kalbe Farma Tbk PT advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Feb 14, 2015. The previous consensus forecast advised that Kalbe Farma Tbk PT would outperform the market.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 19 analysts offering 12 month price targets for Kalbe Farma Tbk PT have a median target of 1,850, with a high estimate of 2,200 and a low estimate of 1,340. The median estimate represents a 6.02% increase from the last price of 1,745. View Full Financials
In 2014, Kalbe Farma Tbk PT reported a dividend of 19.00 IDR, which represents a 11.76% increase over last year. The 16 analysts covering the company expect dividends of 21.73 IDR for the upcoming fiscal year, an increase of 14.38%. View Full Financials
|Div growth (TTM)||+11.76 %|
On Jul 31, 2015, Kalbe Farma Tbk PT reported 2nd quarter 2015 earnings of 12.00 per share. This result was in line with the expectation of the one analyst following the company and exceeded last year's 2nd quarter results by 20.00%. View Full Interim Financials
|Average growth rate||+8.98 %|
Kalbe Farma Tbk PT reported annual 2014 earnings of 44.00 per share on Mar 30, 2015. View Full Annual Financials
|Average growth rate||+12.64 %|
PT. Kalbe Farma Tbk. had 2nd quarter 2015 revenues of 4.47bn. This missed the 4.69bn consensus estimate of the 2 analysts following the company. This was 3.71% above the prior year's 2nd quarter results. View Full Interim Financials
|Average growth rate||+1.06 %|
PT. Kalbe Farma Tbk. had revenues for the full year 2014 of 17.37bn. This was 8.54% above the prior year's results. View Full Annual Financials
|Average growth rate||+14.39 %|